Spartan Bioscience's rapid CYP2C19 genotyping system is being used by cardiologists to personalize antiplatelet therapy with clopidogrel vs. ticagrelor/prasugrel. The system has been widely used by landmark clinical trials (POPular Genetics, TAILOR-PCI) and published in NEJM. The system has FDA 510(k) clearance and is reimbursed by CPT Code 81225.